A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies

NCT06252298 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

74

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Hematologic Malignancies

Interventions

BIOLOGICAL: SCTC21C

Sponsor

Sinocelltech Ltd.